GENE ONLINE|News &
Opinion
Blog

2020-12-07| ChinaIPOSpecial

2020-China’s Biomedicine Industry Ushers New Upsurge of IPO listings

by GeneOnline
Share To
Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange was officially opened for trading and it has since a brought new vitality to China's capital market and the development of China's technology. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list.

GO Prime with only $1.49 now

LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top